

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 March 2002 (14.03.2002)

PCT

(10) International Publication Number
WO 02/21129 A1

- (51) International Patent Classification⁷: G01N 33/535, 33/545
- (74) Agent: WALLEEN, III, John W.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933-7003 (US).
- (21) International Application Number: PCT/US01/26373
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (22) International Filing Date: 24 August 2001 (24.08.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/230,484 6 September 2000 (06.09.2000) US
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant: ORTHO-MCNEIL PHARMACEUTICAL, INC. [US/US]; US Route 202, Raritan, NJ 08869 (US).
- (72) Inventors: THURMOND, Robin; 4654 Constance Drive, San Diego, CA 92115 (US). SUN, Siqian; 13919 Amber Sky Lane, San Diego, CA 92129 (US). KARLSSON, Lars; 336 Fern Glen, La Jolla, CA 92037 (US).
- Published: — with international search report


[Continued on next page]

(54) Title: METHOD OF MONITORING THE EFFECT OF CATHEPSIN S INHIBITORS

Invariant Chain Degradation in PCBMs

(57) Abstract: The present invention relates to a method for monitoring the effect of in vivo administration of Cathepsin S inhibitors by measuring accumulation of an intermediate degradation product of invariant chain (Ii), in particular the p10 Ii fragment, in blood of dosed patients.

DMSO LHVS



← p10Ii



WO 02/21129 A1



— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

TITLE OF INVENTION

METHOD OF MONITORING THE EFFECT OF CATHEPSIN S INHIBITORS

CROSS-REFERENCE TO RELATED APPLICATION

- 5 This application claims the benefit of United States Provisional Application Serial No. 60/230,484, filed 6 September 2000.

FIELD OF THE INVENTION

- 10 The present invention relates to a method for monitoring the effect of in vivo administration of Cathepsin S inhibitors by measuring accumulation of an intermediate degradation product of invariant chain (Ii), in particular the p10 Ii fragment, in blood of dosed subjects.

BACKGROUND OF THE INVENTION

- 15 The recognition of antigen-presenting MHC class II molecules by CD4⁺ T cells is a crucial component of the immunological response. Class II molecules, like other transmembrane proteins, are translocated into the endoplasmic reticulum after synthesis, where they associate with a third protein, the invariant chain (Ii). This molecule is a type II transmembrane protein that serves as a class II-specific chaperone
20 which promotes the exit of class II-Ii complexes from the endoplasmic reticulum and prevents class II molecules from binding peptides and unfolded proteins in the endoplasmic reticulum and in the secretory pathway.

- A targeting motif in the cytoplasmic tail of Ii directs the complexes from the secretory
25 pathway into the endosomal system. Before the MHC class II molecules can present antigen the Ii must be removed. This is accomplished by a series of proteases that break Ii down into small peptides. However, an Ii fragment, called class II-associated invariant chain peptide (CLIP), which occupies the peptide-binding groove of the class II molecule, is in most cases not spontaneously released. The CLIP fragment serves as a
30 substitute peptide that protects the class II binding pocket from collapsing both during intracellular transport and after Ii degradation in the endosomal system. Binding of

antigenic peptides, generated from endocytosed proteins, requires an empty, yet open binding site, and therefore CLIP has to be released while the open binding site needs to be stabilized to allow the binding of other peptides. Human Leukocyte Antigen DM ('HLA-DM') has been well documented to mediate both of these functions, thus promoting the binding of antigenic peptides. After acquiring peptides, the class II molecules are transported to the cell surface via routes that are largely unknown.

Blocking the presentation of antigens is a promising way to inhibit the immune response. This could be done by disrupting the uptake, the proteolytic processing, or binding to MHC class II molecules. Blocking the uptake may be problematic since many different cell types require this function. Inhibition of the proteolytic processing of particular antigens may be of use since different proteases may be involved in cleaving different antigens, however these proteases are not specific and may lead to other side-effects. One way to specifically block the binding to the antigens to the MHC class II is to inhibit the proteolysis of the invariant chain. If this is not removed then the MHC class II molecules cannot be loaded with peptides, hence blocking II degradation would decrease antigen presentation to CD4+ T-cells and disrupt the normal immune response.

Cathepsin S (CatS) is a cysteine protease expressed in lymphatic tissues. It is has been identified as playing a major role in invariant chain proteolysis which is a prerequisite for peptide loading of MHC class II (Riese et al. (1996) *Immunity* 4:357). It has 50-60% identity to cathepsins L and K, but differs in that it has a broad pH optimum that extends to alkaline pH. Inhibitors have been shown in animal models to modulate antigen presentation and are effective in an asthma model (Riese et al., *J. Clin. Invest.* (1998) **101**:2351). Mice deficient in cathepsin S have an impaired ability to present exogenous proteins by professional antigen presenting cells (Nakagawa et al., *Immunity* (1999) **10**:207; Shi et al., *Immunity* (1999) **10**:197).

Compounds that inhibit the proteolytic activity of human cathepsin S are expected to find utility in the treatment of chronic autoimmune diseases including, but not limited to, lupus, rheumatoid arthritis, and asthma; and have potential utility in modulating the immune response to tissue transplantation.

5

Methods of modulating autoimmunity with an agent that modulates cathepsin S activity, e.g. proteolysis of the Ii chain, as well as methods of treating a subject having an autoimmune disorder, methods of evaluating a treatment for its ability to modulate an immune response are described in WO 99/58153.

10

SUMMARY OF THE INVENTION

The present invention concerns a method of or an assay for monitoring the effect of in vivo administration of a cathepsin S inhibitor, said method or assay comprising:

15

- (a) taking a blood sample of the subject treated;
- (b) measuring the accumulation of an intermediate degradation product of invariant chain (Ii) in said blood sample.

More in particular said method comprises:

20

- (a) taking a blood sample of the subject treated;
- (b) purifying the white blood cells from said sample;
- (c) making whole cell lysates of the purified white blood cells;
- (d) analyzing the lysates for presence of an intermediate degradation product of invariant chain (Ii) by a suitable assay method.

25

Suitable assay methods comprise for example Western blot assay or ELISA assay methods. A particular intermediate degradation product of invariant chain (Ii) is p10Ii. In a further aspect, the invention concerns a test kit comprising materials suitable for conducting the above methods or assays.

30

DETAILED DESCRIPTION OF THE INVENTION

Thus the present invention provides a method for monitoring the effect of in vivo administration of Cathepsin S inhibitors, by measuring accumulation of an intermediate degradation product of invariant chain (Ii), i.e. the p10Ii fragment, in blood of dosed subjects.

The said assay of the present invention is particularly useful in a clinical trial setting. However it can also be applied to monitor the effect of Cathepsin S inhibitors in vivo in animal studies, which include but are not limited to monkey, dog, pig, rabbit, guinea pig, and rodents.

The effect of in vivo administration of Cathepsin S inhibitors, in a clinical trial setting, can be monitored by measuring accumulation of an intermediate degradation product of invariant chain (Ii), i.e. the p10Ii fragment, in blood of dosed subjects.

Briefly, after administration of Cathepsin inhibitors for a certain period of time, preferably 16-30hr, blood is drawn and white blood cells are purified, e.g. either by lysis of red blood cells or by a FICOLL gradient centrifugation. Whole cell lysates of WBC are then made and then analyzed by either a Western blot assay or a ELISA assay. For Western assay, cell lysates are first resolved on PAGE gels. After transferring to nitrocellulose membrane, Ii and its intermediate degradation products, including the p10Ii, can then be detected using a mouse mAb against Ii , e.g. Pin1.1, or a rabbit polyclonal antibody against the entire Ii or a peptide fragment. For ELISA assay, a pair of antibodies against Ii, including Pin1.1 and a rabbit polyclonal antibody against C-terminal of p10Ii, can be used.

The said assay can also be applied to monitor effect of Cathepsin S inhibitors in vivo in animal studies, which include but not limit to monkey, dog, pig, rabbit, guinea pig and rodents.

30

The advantage of the invention is that the method is simple and considered more reliable in determining in vivo efficacy of Cathepsin inhibitor compounds.

5 The method can be used to assay the efficacy of Cathepsin inhibitory compounds not only in an experimental screening or clinical setting. It is also useful to monitor patients who have been treated with Cathepsin inhibitors to check efficacy of their treatment and to adjust dosing where necessary. This will allow the prescribing or supervising physician to more precisely and effectively dose the desired cathepsin S inhibitory drug regimen.

10

EXAMPLE 1.

MONITORING CATHEPSIN S INHIBITION IN HUMAN BLOOD

15 The effect of in vivo administration of Cathepsin S inhibitors, in a clinical trial setting, can be monitored by measuring accumulation of an intermediate degradation product of invariant chain (Ii), i.e. the p10Ii fragment, in blood of dosed subjects. Briefly, after administration of Cathepsin inhibitors for a certain period of time, preferably 16-30hr, blood is drawn and white blood cells are purified, e.g. either by lysis of red blood cells or by a FICOLL gradient centrifugation. Whole cell lysates of WBC are then made and
20 analyzed by either a Western blot assay or an ELISA assay. For Western assay, cell lysates are first resolved on SDS-PAGE gels. After transferring to nitrocellulose membrane, Ii and its intermediate degradation products, including the p10Ii, can then be detected using a mouse mAb against Ii , e.g. Pin1.1 or rabbit polyclonal antibodies specific for the C-terminal of the p10Ii fragment. For ELISA assay, a pair of antibodies
25 against Ii, including Pin1.1 and a rabbit polyclonal antibody against C-terminal of p10Ii, can be used. The same assay can also be applied to monitor effect of Cathepsin S inhibitors in vivo in animal studies, for example in monkeys, dogs, pigs, rabbits, guinea pigs, and rodents.

In the present example purified peripheral blood mononuclear cells from human blood were incubated with the cathepsin S inhibitor, LHVS (morpholinurea-leucine-homophenylalanine-vinylsulfonephenyl, also referred to as 4-morpholinecarboxamide, N-
5 [(1S)-3-methyl-1-[[[(1S,2E)-1-(2-phenylethyl)-3-(phenylsulfonyl)-2-propenyl]amino] carbonyl]butyl]- (9Cl)). This compound has been described in US patent no. 5,976,858 and in Palmer et al. (1995) J. Med. Chem. 38:3193 and Riese et al. (1996) Immunity 4:357. After incubation for 24 hours, the samples were run using standard SDS-PAGE protocols, transferred to nitrocellulose membranes and probed with an antibody which recognizes the invariant chain including the p10Ii fragment. In the presence of LHVS
10 the p10Ii fragment can easily be seen (**Figure 1**). This represents a block in the degradation of Ii due to inhibition of cathepsin S.

WHAT IS CLAIMED IS:

1. A method of monitoring the effect of in vivo administration of a cathepsin S inhibitor, said method comprising:
5 a) taking a blood sample of the subject treated;
 b) measuring the accumulation of an intermediate degradation product of invariant chain (Ii) in said blood sample.

2. A method according to claim 1 comprising the steps of:
10 a) taking a blood sample of the subject treated;
 b) purifying the white blood cells from said sample;
 c) making whole cell lysates of the purified white blood cells;
 d) analyzing the lysates for presence of an intermediate degradation product of invariant chain (Ii) by a suitable assay method.
15

3. A method according to claim 2 wherein the suitable assay method in step (d) is Western blotting or ELISA.

4. A method according to claim 1 wherein the intermediate degradation product of
20 invariant chain (Ii) is the p10Ii fragment.


Figures:

Figure 1

Invariant Chain Degradation in PCBM_s

DMSO

LHVS



← p10Ii

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/26373

A. CLASSIFICATION OF SUBJECT MATTER		
IPC(7) : G01N 33/535, 33/545 US CL : 435/7.24		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/7.2, 7.21, 7.23, 7.71, 7.92, 173.4, 173.7, 173.9, 287.7, 964; 436/507, 508, 519, 172, 813; 424/9.2		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) MEDLINE, EMBASE, SCISEARCH, BIOSIS		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99/58153 A1 (BRIGHAM & WOMEN'S HOSPITAL) 18 November 1999	1-3
---	(18.11.1999), see entire document, especially pages 13-17.	-----
Y		4
Y	WO 97/40066 A1 (MASSACHUSETTS INSTITUTE of TECHNOLOGY) 30 October 1997 (30.10.1997), see entire document, especially pages 7-18.	1-4
A/P	US 6,245,904 B1 (MELMS et al.) 12 June 2001 (12.06.2001), see entire document.	1-4
A	US 5,919,639 A (HUMPHREYS et al.) 06 July 1999 (06.07.1999), see entire document.	1-4
Y	SHI G.P. et. al. Role for cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages. Journal of Experimental Medicine. April 2000, vol. 191, No. 7, pages 1177-1186, see abstract.	1-4
Y	Database Medline ACCN. No. 1999:170289. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity. NAKAGAWA et al., see abstract, February 1999.	1-4
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents:		
"A"	document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed	
Date of the actual completion of the international search	Date of mailing of the international search report	
16 November 2001 (16.11.2001)	12 FEB 2002	
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703)305-3230	Authorized officer Gailene R. Gabel <i>Janice Ford for</i> Telephone No. (703) 308-0196	

专利名称(译)	监测组织蛋白酶抑制剂作用的方法		
公开(公告)号	EP1315966A1	公开(公告)日	2003-06-04
申请号	EP2001968093	申请日	2001-08-24
[标]申请(专利权)人(译)	奥索 - 麦克尼尔药品公司		
申请(专利权)人(译)	邻MCNEIL药业, INC.		
当前申请(专利权)人(译)	邻MCNEIL药业, INC.		
[标]发明人	THURMOND ROBIN SUN SIQUAN KARLSSON LARS		
发明人	THURMOND, ROBIN SUN, SIQUAN KARLSSON, LARS		
IPC分类号	G01N33/53 C12Q1/37 G01N33/573 G01N33/535 G01N33/545		
CPC分类号	G01N33/573 C12Q1/37 G01N2333/8139 G01N2333/96466 Y10S435/962 Y10S436/811 Y10S436/813 Y10S436/825 Y10T436/25125 Y10T436/25375		
代理机构(译)	FISHER, ADRIAN JOHN		
优先权	60/230484 2000-09-06 US		
其他公开文献	EP1315966A4 EP1315966B1		
外部链接	Espacenet		

摘要(译)

本发明涉及通过测量给药患者血液中恒定链 (li) , 特别是p10 li片段的中间降解产物的积累来监测组织蛋白酶S抑制剂的体内施用效果的方法。